Michael Geltzeiler Acquires 30,000 Shares of Hyperion DeFi (NASDAQ:HYPD) Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) Director Michael Geltzeiler bought 30,000 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was acquired at an average cost of $3.01 per share, for a total transaction of $90,300.00. Following the completion of the transaction, the director owned 88,015 shares in the company, valued at $264,925.15. This represents a 51.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Hyperion DeFi Stock Up 8.0%

Shares of NASDAQ:HYPD traded up $0.24 during midday trading on Friday, reaching $3.24. The company had a trading volume of 61,636 shares, compared to its average volume of 1,555,262. The stock has a market capitalization of $26.48 million, a P/E ratio of -0.80 and a beta of 2.80. The stock’s fifty day moving average price is $5.40 and its 200-day moving average price is $7.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.25 and a quick ratio of 2.25. Hyperion DeFi, Inc. has a one year low of $0.85 and a one year high of $17.99.

Hyperion DeFi (NASDAQ:HYPD) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $0.36 million during the quarter. Hyperion DeFi had a negative net margin of 62,238.41% and a negative return on equity of 119.59%. Equities research analysts expect that Hyperion DeFi, Inc. will post -41.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on HYPD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Cantor Fitzgerald started coverage on Hyperion DeFi in a report on Tuesday. They issued an “overweight” rating and a $4.00 price target for the company. Finally, Wall Street Zen upgraded Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $3.00.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.